Journal article
Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Studies of Alzheimer Disease
Charles B Malpas, Michael M Saling, Dennis Velakoulis, Patricia Desmond, Rodney J Hicks, Terence J O'Brien
Journal of Computer Assisted Tomography | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
OBJECTIVE: To investigate partial volume correction (PVC) of 2-[F]-fluoro-2-deoxy-D-glucose positron emission tomography in Alzheimer disease in a longitudinal context. METHODS: A total of 115 participants were included, including 55 controls, 53 patients with mild cognitive impairment, and 7 patients with dementia of the Alzheimer type. Imaging was performed at baseline and 24 months. Partial volume corrected vs uncorrected rates of longitudinal change were compared for mesial temporal and cortical regions of interest. RESULTS: Partial volume correction increased apparent uptake, and this effect was greater at 24 months compared with baseline. Partial volume correction decreased the rate of..
View full abstractGrants
Awarded by ADNI (National Institutes of Health)
Awarded by Department of Defense ADNI (Department of Defense)
Awarded by NATIONAL INSTITUTE ON AGING
Funding Acknowledgements
Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and Department of Defense ADNI (Department of Defense Award No. W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer Association; Alzheimer Drug Discovery Foundation; Araclon Biotech; Bio Clinica, Inc; Biogen Idec Inc; Bristol-Myers Squibb Company; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; Euro Immun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Medpace, Inc; Merck and Co, Inc; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Synarc Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.